✦ LIBER ✦

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

✍ Scribed by Wu, Yi-Long; Zhou, Caicun; Hu, Cheng-Ping; Feng, Jifeng; Lu, Shun; Huang, Yunchao; Li, Wei; Hou, Mei; Shi, Jian Hua; Lee, Kye Young; Xu, Chong-Rui; Massey, Dan; Kim, Miyoung; Shi, Yang; Geater, Sarayut L

Book ID: 121512629
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 388 KB
Volume: 15
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70604-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gefitinib versus cisplatin plus docetaxe

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

✍ Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamot 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 239 KB

Gefitinib versus cisplatin plus docetaxe

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

✍ Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamot 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 239 KB

Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib. However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by

Erlotinib versus standard chemotherapy a

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

✍ Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massut 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 246 KB

LUX-lung 3: A randomized, open-label, ph

LUX-lung 3: A randomized, open-label, phase III study of afatinib vs pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations

✍ Schuler, Martin; Yang, James Chih-Hsin; Yamamoto, Nobuyuki; O’Byrne, Ken; Hirsh, 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Erlotinib versus chemotherapy as first-l

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

✍ Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 265 KB

Erlotinib alone or with bevacizumab as f

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

✍ Seto, Takashi; Kato, Terufumi; Nishio, Makoto; Goto, Koichi; Atagi, Shinji; Hoso 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 398 KB